Iambic Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Iambic (Nasdaq: IAM) raised $156M net in October 2026 IPO at $16/share (10.78M shares), closed in October with pro-forma cash of $455M including $47M AbbVie upfront. YTD Q3 2026: collaboration revenue $24M, billings $100M; operating expenses $108M; net loss $88.6M YTD. Signed partnerships with AbbVie (immunology/neuro/oncology, September 2026) and Bayer (June 2026); Takeda collaboration triggered $1M milestone. Launched Enchant v3 AI model (41-billion parameters). Lead clinical candidate IAM1363 showed 36% systemic, 41% intracranial response rates; registrational trial planned 2027. IAM217 (KIF18A) IND approved; IAM-C1 (CDK2/4) IND expected Q4 2026.
Why this rating
Recent IPO provides runway and validates platform; strong partnership billings ($100M YTD) offset R&D spend; clinical progress on three programs material for biotech but company pre-revenue on internal candidates.
Tradability signal
NO TRADE
No trade: positive news with only -3.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $12.80 ▲ 2.32% | at our read · unknown $12.51 | +10 min · unknown $12.63 ▲ 0.96% | +30 min · unknown $11.82 ▼ 5.52% | +1 hr · unknown $11.75 ▼ 6.11% | +4 hrs · unknown $12.67 ▲ 1.28% |
The stock had already moved -2.27% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.